摘要
目的探讨替比夫定联合胸腺素-α1治疗HBe Ag阳性慢性乙型肝炎的疗效及安全性。方法 106例HBe Ag阳性的慢性乙型肝炎患者随机分为替比夫定联合胸腺素-α1治疗组(联合用药组)52例和单用替比夫定治疗组(单用药组)54例,观察两组治疗24周、48周时ALT复常率、HBV-DNA转阴率、HBe Ag转阴率、HBe Ag血清学转换率及不良反应。结果治疗24周时,联合用药组和单用药组HBV-DNA转阴率分别为75.0%(39/52)、77.8%(42/54),差异无统计学意义(P>0.05);联合用药组HBe Ag转阴率为26.9%(14/52),HBe Ag血清学转换率为25.0%(13/52)与单用药组的18.5%(10/54)、16.7%(9/54)相比较,差异均无统计学意义(P>0.05)。治疗48周时,两组HBV-DNA转阴率比较差异无统计学意义[88.5%(46/52)、79.6%(43/54),P>0.05];联合用药组的HBe Ag转阴率为38.5%(20/52),HBe Ag血清学转换率为36.5%(19/52),与单用药组的20.4%(11/54)和18.5%(10/54)相比较,差异有统计学意义(P<0.05)。治疗过程中,两组均未发生严重不良反应。结论替比夫定联合胸腺素-α1治疗HBe Ag阳性慢性乙型肝炎疗效优于单用替比夫定,是安全有效的治疗方法。
Objective To investigate the efficacy and safty of LDT plus thymosin-α1 combination therapy in HBeAg positive chronic hepatitis B（ CHB） patients.Methods One hundred and six patients with chronic hepatitis B were randomly divided into LDT plus thymosin-α1 group 52 cases（ combination therapy group） and LDT group 54 cases（ monotherapy group） .The rate of ALT normali-zation, HBV DNA undetectable, HBeAg loss, HBeAg seroconversion and drug related adverse events were observed at week 24 and 48.Results At week 24, the rate of HBV DNA undetectable was 75.0%（39/52） in the combination therapy group versus 77.8%（42/54） in the monotherapy group（P﹥0.05）;26.9%（14/52） of patients got HBeAg lost, 25.0%（13/52） of patients got HBeAg seroconversed in combination therapy group.When compared with that of 18.5%（10/54）, 16.7%（9/54） in monotherapy group, re-spectively（P〉0.05）.At week 48, the rate of HBV DNA undetectable was 88.5%（46/52） and 79.6%（43/54）, respectively in the combination therapy group and monotherapy group（P﹥0.05）.38.5%（20/52） of patients got HBeAg lost, 36.5%（19/52） of pa-tients got HBeAg seroconversed in combination therapy group.When compared with that of 20.4%（11/54）, 18.5%（10/54） in monotherapy group,respectively（P〈0.05）.No reverse adverse reaction was happened in both groups.Conclusion The combination of telbivudine plus Thymosin-α1 provided significant efficacy and higher safety than telbivudine monotherapy in HBeAg positive chronic hepatitis B（CHB）patients, which is a better combination therapy.
出处
《东南国防医药》
2015年第4期342-345,352,共5页
Military Medical Journal of Southeast China
基金
"十二五"国家科技重大专项(2012ZX10002003-005)
